| Bioactivity | Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research[1][2]. |
| Target | Factor D |
| In Vivo | Lampalizumab 经静脉注射给食蟹猴后，5小时内血清因子D水平增加近10倍，有效中和了其抑制活性[1]。 |
| Name | Lampalizumab |
| CAS | 1278466-20-8 |
| Molar Mass | 46.96 (kDa) |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yuan X, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017 Mar;102(3):466-475. [2]. Hanus J, et al. Current therapeutic developments in atrophic age-related macular degeneration. Br J Ophthalmol. 2016 Jan;100(1):122-7. |